Mediland Pharm Limited, together with subsidiaries, engages in the retail sale of health, beauty, and wellness products in Australia and New Zealand.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.07|
|52 Week High||AU$0.043|
|52 Week Low||AU$0.11|
|1 Month Change||20.69%|
|3 Month Change||-2.78%|
|1 Year Change||-30.00%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-66.67%|
Recent News & Updates
Mediland Pharm (ASX:MPH) Is Carrying A Fair Bit Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
|MPH||AU Specialty Retail||AU Market|
Return vs Industry: MPH underperformed the Australian Specialty Retail industry which returned 24.7% over the past year.
Return vs Market: MPH underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: Insufficient data to determine MPH's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine MPH's volatility change over the past year.
About the Company
Mediland Pharm Limited, together with subsidiaries, engages in the retail sale of health, beauty, and wellness products in Australia and New Zealand. The company’s stores also offers luxury products, such as opal and pink diamond jewelry pieces, souvenirs and gifts, luxurious bedding and rugs. It operates through one direct store in Australia; one store in Auckland, New Zealand; six franchise shops in China; three WeChat accounts; and four e-commerce platforms.
Mediland Pharm Fundamentals Summary
|MPH fundamental statistics|
Is MPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MPH income statement (TTM)|
|Cost of Revenue||AU$1.10m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.02|
|Net Profit Margin||-541.20%|
How did MPH perform over the long term?See historical performance and comparison
Is Mediland Pharm undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MPH's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MPH's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MPH is unprofitable, so we can't compare its PE Ratio to the Australian Specialty Retail industry average.
PE vs Market: MPH is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MPH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MPH is overvalued based on its PB Ratio (7.2x) compared to the AU Specialty Retail industry average (3.9x).
How is Mediland Pharm forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Retail industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mediland Pharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Mediland Pharm performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MPH is currently unprofitable.
Growing Profit Margin: MPH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MPH is unprofitable, and losses have increased over the past 5 years at a rate of 61.8% per year.
Accelerating Growth: Unable to compare MPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MPH is unprofitable, making it difficult to compare its past year earnings growth to the Specialty Retail industry (91.8%).
Return on Equity
High ROE: MPH has a negative Return on Equity (-207.45%), as it is currently unprofitable.
How is Mediland Pharm's financial position?
Financial Position Analysis
Short Term Liabilities: MPH's short term assets (A$3.9M) exceed its short term liabilities (A$2.6M).
Long Term Liabilities: MPH's short term assets (A$3.9M) do not cover its long term liabilities (A$4.2M).
Debt to Equity History and Analysis
Debt Level: MPH's debt to equity ratio (83%) is considered high.
Reducing Debt: Insufficient data to determine if MPH's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MPH has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MPH has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 24% each year.
What is Mediland Pharm current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MPH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MPH's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Yeshween Mudaliar, also known as Yesh, is Managing Director and Director of Mediland Pharm Limited since August 27, 2018. Mr. Mudaliar is a professional hospitality executive with industry experience....
CEO Compensation Analysis
Compensation vs Market: Yesh's total compensation ($USD82.03K) is below average for companies of similar size in the Australian market ($USD302.06K).
Compensation vs Earnings: Yesh's compensation has been consistent with company performance over the past year.
Experienced Management: MPH's management team is considered experienced (3 years average tenure).
Experienced Board: MPH's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Mediland Pharm Limited's employee growth, exchange listings and data sources
- Name: Mediland Pharm Limited
- Ticker: MPH
- Exchange: ASX
- Founded: 2002
- Industry: Specialty Stores
- Sector: Retail
- Market Cap: AU$21.893m
- Shares outstanding: 312.76m
- Website: https://www.medilandpharm.com.au
- Mediland Pharm Limited
- 18-40 Anderson Street
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 07:04|
|End of Day Share Price||2021/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.